J&J's canagliflozin may raise heart risks

01/9/2013 | USA Today · Bloomberg

An FDA panel on Tuesday concluded that Johnson & Johnson's experimental diabetes drug canagliflozin may slightly raise the odds of heart attack, stroke or death as it increased bad cholesterol levels in patients compared with two other diabetes medications. The drug, part of a class known as SGLT2 inhibitors, might help control blood glucose levels in patients with type 2 diabetes, as well as aid in weight loss and lowering blood pressure, a company spokesman said.

View Full Article in:

USA Today · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA